Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $117.30 | Total: $586.50 |
| 1 | 10 | $99.36 | Total: $993.60 |
| 1 | 25 | $84.18 | Total: $2,104.50 |
| 1 | 50 | $71.76 | Total: $3,588.00 |
| 1 | 100 | $62.10 | Total: $6,210.00 |
Overview
Navoximod (GDC-0919) (NLG- 919, GDC-0919) is a potent indoleamine-(2,3)-dioxygenase (IDO) pathway inhibitor (KiEC50: 7 nM75 nM).
Chemical Properties
| Molecular Formula | C18H21FN2O2 |
| Molecular Weight | 316.37 |
| CAS Numbers | 1402837-78-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [H][C@@]1(CC[C@H](O)CC1)[C@H](O)C[C@H]1c2c(cccc2F)-c2cncn12 |
Storage and Handling
0C Short Term, -20C Long Term
References
Mario R. Mautino, et al. Abstract 491 NLG919, a novel indoleamine-2,3-dioxygenase [IDO]-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.